Metabolites as drivers and targets in Rheumatoid Arthritis.
Hanlon MM, Canavan M, Barker BE, Fearon U. Clin Exp Immunol. 2021 Nov 27
Canavan M, Marzaioli V, Bhargava V, Nagpal S, Gallagher P, Hurson C, Mullan R, Veale DJ, Fearon U. Front Immunol. 2021 Oct 7
Floudas A, Neto N, Orr C, Canavan M, Gallagher P, Hurson C, Monaghan MG, Nagpar S, Mullan RH, Veale DJ, Fearon U. Ann Rheum Dis. 2021 Oct 1
O’Brien A, Hanlon MM, Marzaioli V, Wade SC, Flynn K, Fearon U, Veale DJ. Front Immunol. 2021 Jun 24
Turk M, Murray K, Alammari Y, Gorman A, Young F, Gallagher P, Saber T, Freeman L, Maguire S, O’Shea F, Fearon U, Veale D. RMD Open. 2021 Apr
ACPA Status Correlates with Differential Immune Profile in Patients with Rheumatoid Arthritis
Floudas A, Canavan M, McGarry T, Mullan R, Nagpal S, Veale DJ, Fearon U. Cells.2021 Mar 14
Serum miRNA Signature in Rheumatoid Arthritis and “At-Risk Individuals”.
Cunningham CC, Wade S, Floudas A, Orr C, McGarry T, Wade S, Cregan S, Fearon U, Veale DJ. Front Immunol. 2021 Mar 3;12:633201. doi: 10.3389/fimmu.2021.633201. eCollection 2021.
First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis.
Murray K, Floudas A, Murray C, Fabre A, Crown J, Fearon U, Veale D. BMJ Case Rep. 2021 Feb 4
Murray K, Quinn S, Turk M, O’Rourke A, Molloy E, O’Neill L, Mongey AB, Fearon U, Veale DJ. Rheumatology (Oxford). 2021 Feb 1.
McGarry T, Hanlon MM, Marzaioli V, Cunningham CC, Krishna V, Murray K, Hurson C, Gallagher P, Nagpal S, Veale DJ, Fearon U. Clin Transl Immunology . 2021 Jan 19.
Long-term remission and biologic persistence rates: 12-year real-world data.
Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, Fearon U, Veale DJ. Arthritis Res Ther. 2021 Jan 13;23(1):25. doi: 10.1186/s13075-020-02380-z.
The PD-1:PD-L1 axis in Inflammatory Arthritis.
Canavan M, Floudas A, Veale DJ, Fearon U. BMC Rheumatol. 2021 Jan 11;5(1):1. doi: 10.1186/s41927-020-00171-2.